Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Accumulated Expenses (2022 - 2025)

Historic Accumulated Expenses for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $65.3 million.

  • Phathom Pharmaceuticals' Accumulated Expenses rose 8274.84% to $65.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.3 million, marking a year-over-year increase of 8274.84%. This contributed to the annual value of $53.2 million for FY2024, which is 20954.24% up from last year.
  • Latest data reveals that Phathom Pharmaceuticals reported Accumulated Expenses of $65.3 million as of Q3 2025, which was up 8274.84% from $64.3 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' 5-year Accumulated Expenses high stood at $65.3 million for Q3 2025, and its period low was $7.6 million during Q1 2022.
  • For the 4-year period, Phathom Pharmaceuticals' Accumulated Expenses averaged around $27.3 million, with its median value being $16.5 million (2024).
  • In the last 5 years, Phathom Pharmaceuticals' Accumulated Expenses surged by 124.92% in 2023 and then surged by 20954.24% in 2024.
  • Phathom Pharmaceuticals' Accumulated Expenses (Quarter) stood at $14.7 million in 2022, then grew by 17.16% to $17.2 million in 2023, then surged by 209.54% to $53.2 million in 2024, then rose by 22.76% to $65.3 million in 2025.
  • Its Accumulated Expenses was $65.3 million in Q3 2025, compared to $64.3 million in Q2 2025 and $43.0 million in Q1 2025.